Janssen’s JNJ-2113 holds potential to become leading treatment for psoriasis: GlobalData EP News Bureau Aug 1, 2023 JNJ-2113, a novel, first-in-class oral interleukin 23 receptor (IL-23R) antagonist peptide in adult patients with…
